21.07.2022 Marinomed Biotech AG  ATMARINOMED6

DGAP-News: Marinomed to pause issuing of tranches of Convertible Notes Funding Program to Nice & Green


DGAP-News: Marinomed Biotech AG / Key word(s): Agreement
Marinomed to pause issuing of tranches of Convertible Notes Funding Program to Nice & Green

21.07.2022 / 07:45
The issuer is solely responsible for the content of this announcement.

Marinomed to pause issuing of tranches of Convertible Notes Funding Program to Nice & Green

  • Flexible financing agreement with Nice & Green allows for temporary pausing in respect of the current market environment and the stable financial position
  • Partnership with Nice & Green continues and roadshow support ongoing

Korneuburg, Austria, 21 July 2022 – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics, today announced that it has agreed with Nice & Green S.A. to currently not issue further tranches as part of the Convertible Notes Funding Program (CNFP) that the companies had entered on 04 October 2021. Marinomed believes that with the current situation at the stock markets and its stable financial position, it should reduce the dilutive impact on Marinomed‘s shareholders.

Pascal Schmidt, CFO of Marinomed, commented: “As we are refining our strategy to unlock the potential of our validated platform technologies in new indications with high unmet medical needs, we appreciate the high degree of flexibility offered by the financing agreement with Nice & Green. With Nice & Green, we have a reliable partner and investor that is market-focused and respects our financing needs in the context of our current strategic objectives.”

Benoit Villers, Managing Partner of Nice & Green said: “This right to suspend the financing program enables Marinomed to better adapt the funding plan to its cash flow forecasting and capital needs. We are pleased to bring more financial flexibility to Marinomed’s management team, and we will continuously support their short and long-term needs.”

In addition to the CNFP, the agreement between the two companies includes a commitment by Nice & Green S.A to leverage its network of small- and mid-cap investors as both companies are committed to a productive and successful long-term partnership.

About Nice & Green
Nice & Green is a privately held equity financing firm providing tailor-made and flexible financing solutions for listed Micro-, Small- and Mid-Cap companies in Europe. Nice & Green works towards improving financing solutions to better meet the evolving capital raising needs of listed companies. It strives to create value for both the companies and their shareholders, thanks to a virtuous approach for investment. Find out more at nicengreen.ch.

About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of iota-carrageenan. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. Marinomed also develops drugs for other serious viral infectious diseases based on iota-carrageenan. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.


For further inquiries contact:

Marinomed Biotech AG                  
PR: Lucia Mayr-Harting
T +43 2262 90300 158
Email: [email protected]
IR: Stephanie Kniep
T +43 2262 90300 226
Email: [email protected]
International Media Contact
MC Services AG
Dr. Brigitte Keller, Dr. Regina Lutz
T +49 89 210228 0
UK: Shaun Brown
M: +44 7867 515 918
Email: [email protected]



This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.

21.07.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Phone: +43 2262 90300
Fax: +43 2262 90300-500
E-mail: [email protected]
Internet: www.marinomed.com
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market)
EQS News ID: 1402423

End of News DGAP News Service

1402423  21.07.2022 


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022
Umsatzerlöse1 2,61 4,81 4,67 6,14 8,12 11,63 11,28
EBITDA1,2 -1,34 -1,44 -4,90 -5,88 -5,39 -3,54 -4,24
EBITDA-Marge3 -51,34 -29,94 -104,93 -95,77 -66,38 -30,44 -37,59
EBIT1,4 -1,53 -1,64 -5,14 -6,21 -5,82 -4,14 -4,91
EBIT-Marge5 -58,62 -34,10 -110,06 -101,14 -71,67 -35,60 -43,53
Jahresüberschuss1 -1,97 -2,38 -12,10 -7,22 -6,01 -5,89 -6,40
Netto-Marge6 -75,48 -49,48 -259,10 -117,59 -74,01 -50,65 -56,74
Cashflow1,7 -2,53 -2,18 -4,32 -7,64 -6,89 -4,87 -5,20
Ergebnis je Aktie8 -1,97 -2,38 -12,10 -5,10 -4,10 -4,00 -4,30
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

Marinomed Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2N9MM 43,700 Halten 66,39
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -9,44
-15,97 - 5,89 -19,05
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
0,00 0,00 0,00 21.06.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
23.05.2023 17.08.2023 21.11.2023 19.04.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
19,21% -12,03% -22,24% -40,79%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Marinomed Biotech AG  ISIN: ATMARINOMED6 können Sie bei EQS abrufen

Biotechnologie , A2N9MM , MBG , FWB:MBG